MD&M East

Medtronic Scores FDA Nod for Next-Gen InterStim

Medtronic continues to up its game in sacral neuromodulation. FDA approved InterStim X, the next generation of the company's InterStim portfolio's recharge-free device. Medtronic said implants have ...
MobiHealthNews

FDA approves Medtronic’s multi-implant smart programmer

The FDA has approved an app-based smart programming device used to discreetly and easily control implants treating for overactive bladder (OAB), chronic fecal incontinence (FI) and non-obstructive ...
BioWorld

Medtronic’s next-gen Interstim X system wins FDA nod

The FDA has approved Medtronic plc’s next-generation sacral neuromodulation (SNM) system, Interstim X, giving patients a recharge-free option with a 10-year+ lifespan. This newest member of the ...
Becker's ASC

Study: InterStim Incontinence Therapy Still Effective After 3 Years

A new multicenter study shows use of Medtronic’s InterStim Therapy via sacral nerve stimulation reduced incontinent episodes and improved quality of life in most patients with chronic fecal ...
AOL

Medtronic ratchets up patent spat for device that aids in bladder, bowel control

Medtronic is upping the ante in patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic's InterStim device, an implanted ...